Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors

George D Demetri, Patricia Lo Russo, Iain R J MacPherson, Ding Wang, Jeffrey A Morgan, Valerie G Brunton, Prashni Paliwal, Shruti Agrawal, Maurizio Voi, T R Jeffry Evans

Research output: Contribution to journalArticlepeer-review

Abstract

To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and recommended phase II dose of dasatinib in metastatic solid tumors refractory to standard therapies or for which no effective standard therapy exists.
Original languageEnglish
Pages (from-to)6232-40
Number of pages9
JournalClinical Cancer Research
Volume15
Issue number19
DOIs
Publication statusPublished - 2009

Fingerprint

Dive into the research topics of 'Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors'. Together they form a unique fingerprint.

Cite this